论文部分内容阅读
目的探讨吉西他滨联合顺铂方案治疗晚期非小细胞肺癌的疗效。方法随机抽取我院2012年2月至2013年2月收治的84例静脉化疗治疗晚期非小细胞肺癌患者,根据治疗方法的不同分为两组,对照组患者采用吉西他滨治疗,观察组患者则采用吉西他滨+顺铂方案介入联合静脉化疗治疗,针对两组患者治疗效果进行评价,并综合分析吉西他滨+顺铂方案的疗效。结果对照组治疗有效率为71.4%,观察组治疗有效率为97.6%,观察组治疗有效率明显高于对照组,差异有统计学意义(P<0.05);对照组12例(28.6%)发生不良反应,观察组1例(2.4%)发生不良反应,观察组不良反应控制效果明显优于对照组,差异有统计学意义(P<0.05)。结论吉西他滨+顺铂方案介入联合静脉化疗治疗晚期非小细胞肺癌的疗效确切、安全可靠。
Objective To investigate the efficacy of gemcitabine combined with cisplatin in the treatment of advanced non-small cell lung cancer. Methods Eighty-four patients with advanced non-small cell lung cancer who underwent intravenous chemotherapy in our hospital from February 2012 to February 2013 were randomly divided into two groups according to the different treatment methods. Patients in the control group were treated with gemcitabine and patients in the observation group Gemcitabine + cisplatin intervention in the treatment of intravenous chemotherapy for the treatment of two groups were evaluated, and comprehensive analysis of the efficacy of gemcitabine + cisplatin regimen. Results The effective rate was 71.4% in the control group and 97.6% in the observation group. The effective rate of the observation group was significantly higher than that of the control group (P <0.05), and 12 cases (28.6%) of the control group Adverse reactions, 1 case (2.4%) observed adverse reactions, the observation group adverse reaction control effect was significantly better than the control group, the difference was statistically significant (P <0.05). Conclusion The combination of gemcitabine and cisplatin in the treatment of advanced non-small cell lung cancer with intravenous chemotherapy is effective, safe and reliable.